Adalimumab

Therapeutic Group

Immunosuppressants

Indication Dosage

Indication:

Adalimumab is a monoclonal antibody that works by blocking TNF-alpha, a protein responsible for inflammation. It is used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa. By reducing inflammation, it helps relieve symptoms like joint pain, swelling, and skin lesions, improving the patient’s quality of life.

Dosage:

  • Rheumatoid & Psoriatic Arthritis: 40 mg every 2 weeks
  • Ankylosing Spondylitis: 40 mg every 2 weeks
  • Crohn’s Disease & Ulcerative Colitis: 160 mg on Day 1, then 80 mg on Day 15, followed by 40 mg every 2 weeks
  • Plaque Psoriasis: 80 mg first dose, then 40 mg every 2 weeks

Content

  • Prefilled Syringe 20mg/0.4ml, 40mg/0.8ml, 80mg/0.8ml: Adalimumab 20mg/0.4ml, 40mg/0.8ml, 80mg/0.8ml

Pregnancy

Only if Necessary

Stability

  • Immunosuppressant / TNF-Alpha Inhibitor

Contra Indications

  • Adalimumab is contraindicated in patients with severe infections (e.g., active tuberculosis, sepsis), hypersensitivity to the drug, moderate to severe heart failure, and demyelinating disorders (e.g., multiple sclerosis).

Precautions

  • Adalimumab is contraindicated in patients with severe infections (e.g., active tuberculosis, sepsis), hypersensitivity to the drug, moderate to severe heart failure, and demyelinating disorders (e.g., multiple sclerosis).

Lactation

  • Only if Necessary

Side Effects

  • Increased Risk of Infections (TB, Fungal, Bacterial)
  • Injection Site Reactions (Redness, Swelling, Pain)
  • Headache
  • Nausea
  • Fatigue
  • Rash & Itching
  • Liver Enzyme Elevation
  • Joint & Muscle Pain
  • High Blood Pressure
  • Increased Risk of Cancer (Rare Cases)

Available Brands